Skip to content
TrialScanner

NCT02017912

Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS

Phase 2CompletedBCLILead

Registry record

Lead sponsor
Brainstorm-Cell Therapeutics
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Primary completion
Mar 2016Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02017912 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02017912: Phase 2, Randomized, Double... | TrialScanner